Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28958068 | 0.85 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16070169 | 0.85 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20230990 | 0.85 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29132357 | 0.83 | — | — | |
| SCHEMBL25133345 | 0.83 | — | — | |
| SCHEMBL30769428 | 0.80 | — | — | |
| SCHEMBL8734417 | 0.80 | — | — | |
| SCHEMBL31335115 | 0.80 | CHRM2 (0.35) | — | |
| SCHEMBL5444117 | 0.79 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3CPN1CPB2 | |
| SCHEMBL31584249 | 0.78 | DRD2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617889-B1 | Polymers for use as anion exchange membranes | ENVISION ENERGY USA LTD. (US) | 2026-05-05 | — | — | US | claimed |
| CN-112661694-B | Preparation method of 4- (dimethoxymethyl) -piperidine | 西安凯立新材料股份有限公司 | 2023-04-11 | — | — | CN | claimed |
| US-20220274955-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-09-01 | — | — | US | claimed |
| CN-114085213-B | Preparation method of ARV-471 | 苏州国匡医药科技有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114085213-A | Preparation method of ARV-471 | 苏州国匡医药科技有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-112661694-A | Preparation method of 4- (dimethoxymethyl) -piperidine | 西安凯立新材料股份有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20260146044-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | INCRELAND (CN) | 2026-05-28 | — | — | US | disclosed |
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4748840-A1 | IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF | TAINUORUI (TIANJIN) BIOTECHNOLOGY CO., LTD (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4745142-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Increland (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-122070287-A | IRAK 4-targeted degradation agent compound and application thereof | 江苏先声药业有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-116917280-B | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-1880996-A1 | Spiroindolinepiperidine derivatives | Syngenta Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| EP-1515969-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | Syngenta Limited (GB) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106457-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2003-12-24 | — | — | WO | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146044-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | IRAK4, IRAK2, IRAK1 | SLC6A2 3829/4885SLC6A4 2666/4885SLC6A3 3402/4885 |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | SLC6A2 3400/4885SLC6A4 4257/4885SLC6A3 3658/4885 |
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | SGK1, PBK, SGK3 | SLC6A2 4152/4885SLC6A4 2996/4885SLC6A3 3265/4885 |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | SLC6A2 443/4885SLC6A4 583/4885SLC6A3 417/4885 |
| US-20220274955-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | SLC6A2 4566/4885SLC6A4 4229/4885SLC6A3 4209/4885 |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | RECQL, OPRD1, NCAPD3 | SLC6A2 3045/4885SLC6A4 3459/4885SLC6A3 2661/4885 |
| US-12617889-B1 | Polymers for use as anion exchange membranes | KCNN3, KCNJ1, KCNH3 | SLC6A2 1311/4885SLC6A4 690/4885SLC6A3 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.